Latest stories on HELP
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
Business Insider56 · neutralgeneral
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
Business Insider56 · neutralgeneral
HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62
Stocktwits News73 · bullishanalyst
Helus Pharma CEO to Spotlight Mental Health Pipeline at Canaccord Growth Conference
TipRanks56 · neutralgeneral
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
Business Insider55 · neutralgeneral
Helus Pharma Names Former Intra-Cellular President Michael Halstead as CEO Amid Phase 3 MDD Push
TipRanks56 · neutralgeneral
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
Stocktwits News56 · neutralanalyst
Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003
TipRanks63 · neutralproduct/pr
HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs
Stocktwits News73 · bullishproduct/pr
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
PR Newswire67 · bullishproduct/pr
Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results?
Yahoo Finance56 · neutralanalyst
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
Seeking Alpha63 · neutralanalyst
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results | HELP Stock News
StockTitan38 · neutralearnings
Cybin: A Speculative Bet On Their Pivotal Depression Readout
Seeking Alpha58 · neutralanalyst
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
PR Newswire67 · bullishproduct/pr
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering | HELP Stock News
StockTitan26 · bearishgeneral
Helus Pharma’s $50 Million Offering Aims to Accelerate Key Mental Health Drug Trials
MarketChameleon24 · bearishgeneral
Helus Pharma prices $50M public offering at $4.85 per share
Seeking Alpha24 · bearishgeneral
Helus Pharma™ Announces US$50 Million Underwritten Offering | HELP Stock News
StockTitan26 · bearishgeneral
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress | HELP Stock News
StockTitan56 · neutralproduct/pr
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference | HELP Stock News
StockTitan55 · neutralproduct/pr
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York | HELP Stock News
StockTitan56 · neutralgeneral